id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-315453-mbv8vb2r	Jean, Shio-Shin	Old and re-purposed drugs for the treatment of COVID-19	2020-06-01		.txt	text/plain	3462	169	40	EXPERT OPINION: Although strong evidence of well-designed randomized controlled studies regarding COVID-19 therapy is presently lacking, remdesivir, teicoplanin, hydroxychloroquine (not in combination with azithromycin), and ivermectin might be effective antiviral drugs and are deemed promising candidates for controlling SARS-CoV-2. In future, clinical trials regarding a combination of potentially effective drugs against SARS-CoV-2 need to be conducted to establish the optimal regimen for the treatment of patients with moderate-to-severe COVID-19. Recently, US Food and Drug Administration (FDA) approved the phase 3, double-blind ODYSSEY study (ClinicalTrials.gov Identifier: NCT04326426, initiated on 12 April 2020) to investigate the efficacy and safety of tradipitant at a dosage of 85 mg orally twice daily for the treatment of inflammatory lung injury following critical COVID-19 infection [35] . Apart from remdesivir that was shown to have acceptable clinical efficacy against moderate-to-severe COVID-19 and acceptable side effects, the potential antiviral drugs that are likely useful in the treatment of patients with mild-to-moderate COVID-19 included hydroxychloroquine, teicoplanin, and ivermectin.	./cache/cord-315453-mbv8vb2r.txt	./txt/cord-315453-mbv8vb2r.txt